Neil S. Belloff

Neil S. Belloff (chief executive) discloses dealings in Eloxx Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 30 January 2020 to 30 July 2021, the count stands at 20 filings.

The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.

Most recently, on 30 July 2021, the filings show a share grant worth €509 in Eloxx Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.